An immunomodulatory molecular analogue of thalidomide, which has shown promise in phase 2 studies for managing myeloma, and possibly other cancers.
Adverse effects BM suppression with anaemia, thrombocytopaenia, neutropaenia, diarrhoea, fever, muscle cramps, neuropathy, constipation, rash, fatigue.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
James Evans, a pharmaceutical industry analyst in visiongain, said: “The years 2012 to 2013 will see two important new products reach the market, Onyx's Kyprolis and Celgene's Actimid. Both of these have advantages over current drugs, but they're basically incremental improvements on what we already have - proteasome inhibitors and immunomodulators.